Calidi to Showcase CLD-401 IL-15 Superagonist Data at April AACR Meeting
Calidi Biotherapeutics will present new preclinical data on its lead RedTail platform candidate CLD-401, a tumor-selective oncolytic virus engineered to express IL-15 superagonist in the tumor microenvironment, at the AACR annual meeting April 17–22, 2026. The company plans to file an IND for CLD-401 by end of 2026.
1. AACR Presentation
Calidi Biotherapeutics will present new preclinical data on its lead asset, CLD-401, at the American Association for Cancer Research annual meeting in San Diego from April 17–22, 2026.
2. CLD-401 Mechanism and Development
CLD-401 is a systemically delivered oncolytic virus from the RedTail platform, engineered to express high levels of IL-15 superagonist specifically within the tumor microenvironment, demonstrating targeted T-cell and NK-cell activation in IND-enabling studies.
3. Regulatory Timeline and Partnerships
The company expects to file an IND for CLD-401 by the end of 2026 and is actively pursuing strategic partnerships to accelerate clinical development and expand its RedTail platform applications.